Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Exclusion criteria

• ✕. Cyclosporine (Restasis, Cequa etc.) or Xiidra within 60 days prior to enrollment;
• ✕. Antihistamines (oral or topical) within 10 days prior to enrollment;
• ✕. Systemic medication(s) (other than antihistamines) that is known to cause ocular dryness (e.g. diuretics, anti-hypertensives, anti-depressants, hormone therapy) and whose dose of this medication(s) has not been stable within 30 days prior to enrollment. There must be no anticipated adjustments to the dose of these medications for the duration of the trial;
• ✕. Accutane (at any time);
• ✕. Oral tetracyclines or azithromycin within 30 days prior to enrollment; or
• ✕. Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, non-steroidal anti- inflammatory medications within 30 days prior to enrollment.
• ✕. Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation \[Lipiflow\], iLux etc.) within 12 months prior to enrollment either as part of routine care or clinical investigation;
• ✕. Meibomian gland expression within 6 months prior to enrollment;